

PRESS RELEASE

Paris and Toulouse, November 24, 2014

**GENTICEL WINS THE DELOITTE TECHNOLOGY FAST 50
“PRIX BIOTECH D'AVENIR 2014” AWARD**

GENTICEL (Euronext Paris & Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, has won the 1st “Prix Biotech d’Avenir 2014” (*Most Promising Biotech Award*) in Biotech - Life Sciences of SW France of the Deloitte Technology Fast 50 benchmark awards for technology companies.

The Deloitte Technology Fast 50 program recognizes fast-growing innovative technology companies. For its Life Sciences awards, growth is measured by the amount of capital raised during the financial year 2013.

The Technology Fast 50 regional jury chose to recognize Genticel for its excellent performance in capital increase in 2013 prior to its market listing in April 2014. Genticel has raised €18.2 million in 2013, one of the most significant capital increases in the Life Sciences sector in Europe for that year (excluding listed companies).

Genticel specializes in the innovative sector of therapeutic vaccines aimed at preventing cervical cancer. The candidate therapeutic vaccines developed by Genticel are designed to eliminate, at an early stage, cells carrying the human papillomavirus (HPV) responsible for cervical cancer, one of the most common forms of cancer amongst women worldwide.

After promising results from the Phase I clinical trial for Genticel’s flagship product, ProCervix, a Phase II trial began in early 2014. Genticel completed earlier this month, more than 4 months ahead of schedule, the patient enrollment for this Phase II trial. 239 patients have been enrolled at 39 clinics across 7 different European countries. The program’s current patient dropout rate of less than 1% during clinical trials serves as a clear indicator of the determination these women, infected with HPV16 or HPV18, have to undergo treatment.

ProCervix will be the first drug to address this unmet medical need. Today, women affected by the virus have no alternative other than watchful waiting until the infection spontaneously regresses or until it leads to precancerous lesions requiring surgery.

“This trophy is a wonderful recognition of our strategy that includes giving Genticel the financial means necessary for the clinical development of its innovative candidate drugs,” said Benedikt Timmerman, Chief Executive Officer of Genticel.



Upcoming events:

Genticel will take part in various investor events over the coming months:

Petercam Healthcare CEO Seminar - Brussels
JP Morgan Healthcare Conference - San Francisco

November 27, 2014
January 12 - 15, 2015

About Genticel

Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.

Genticel is developing ProCervix, a first therapeutic vaccine in Phase II clinical trials, designed to eliminate cervical cells infected with HPV 16 and/or HPV 18. The company has also established Vaxiclase, a technology platform ideally adapted for use in early-intervention immunotherapies against multiple infectious or cancerous diseases. This platform is being used to develop a second therapeutic vaccine candidate, now in its preclinical stage, targeting six of the most pertinent HPV strains in terms of global epidemiology.

Genticel is based in Paris and Toulouse and was awarded "Prix Biotech d'Avenir 2014" in SW France category of the Deloitte Technology Fast 50 benchmark.

Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels.

For more information, please visit www.genticel.com



CONTACT GENTICEL

Benedikt Timmerman
Chief Executive Officer
investors@genticel.com

INVESTOR CONTACT

Corinne Puissant
Tel.: +33 (0)1 53 67 36 57
cpuissant@actus.fr

PRESS CONTACT

Alexandra Prisa
Tel.: +33 (0)1 53 67 35 79
aprisa@actus.fr